Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire files Vyvanse drug for the treatment of ADHD in adults
Vyvanse is a prodrug stimulant that is therapeutically inactive until metabolized in the body and active d-amphetamine is released. Shire says the drug is different from other oral
Vyvanse is a prodrug stimulant that is therapeutically inactive until metabolized in the body and active d-amphetamine is released. Shire says the drug is different from other oral
Within this additional program, Galapagos will progress a disease-modifying drug towards completion of clinical phase IIa, at which point GSK’s R&D organization will be responsible for the late-stage
The approval covers the drug in 2.5mg, 5mg and 10mg doses. Shipment of the product will begin shortly. Teva’s tablets are the AB-rated generic equivalent of Pfizer’s Norvasc
The new drug application was filed after a 209 randomized patient, placebo-controlled clinical trial was conducted, which subsequently met the primary endpoints in all three dosing arms. Akorn
Terms of the agreement include a cash settlement of JPY30.4 billion (approximately $250 million) to be paid by Lion to Bristol-Myers Squibb. Bristol-Myers Squibb is selling the rights
The company said that the modified intent-to-treat clinical cure rate for cethromycin was 82.9%, compared to 88.5% for Biaxin. Under this analysis, the study met the endpoint of
Angiox is an anticoagulant used in patients undergoing percutaneous coronary interventions (PCI), commonly referred to as angioplasty. The product is approved in 26 European markets. The Medicines Company
The US agency said the company had not demonstrated the efficacy of the painkiller, because statistical analysis of data from the trials did not address missing data from
Genmab is now planning to expand the antibody’s development in cancer, specifically the existing non-cutaneous T-cell lymphoma and cutaneous T-cell lymphoma clinical programs, and to create a unibody
The trial is expected to enroll approximately 800 patients at around 100 clinical centers in North America and Europe and is the final phase III trial in NicOx’s